GPR108: A Potential Drug Target for Psychiatric Disorders and Cancer
GPR108: A Potential Drug Target for Psychiatric Disorders and Cancer
GPR108 (GP108_HUMAN) is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and psychiatric disorders. GPR108 is a member of the G-protein-coupled receptor (GPCR) family, which is a large superfamily of transmembrane proteins that play a key role in cellular signaling.
GPR108 is expressed in various tissues and cells in the body, including the brain, nervous system, and endothelial cells. It is known to be involved in the regulation of cellular processes that are important for brain development, function, and survival, including neuronal signaling, neurotransmitter release, and cell survival.
Studies have suggested that GPR108 may be involved in the development and progression of various psychiatric disorders, including depression, anxiety, and schizophrenia. For example, GPR108 has been shown to be expressed in the brains of individuals with major depressive disorder (MDD) and has been involved in the regulation of neurotransmitter release in these individuals.
In addition to its potential role in psychiatric disorders, GPR108 has also been suggested as a potential drug target for cancer. For example, GPR108 has been shown to be involved in the regulation of angiogenesis, which is the process by which new blood vessels form in tumors. This may make it a useful target for cancer treatments that target angiogenesis.
GPR108 has also been shown to be involved in the regulation of pain perception and neuroinflammation, which are important factors in the development and progression of chronic pain and neuroinflammatory diseases.
In conclusion, GPR108 is a promising drug target or biomarker for a variety of psychiatric and neurological disorders. Further research is needed to fully understand its role in these conditions and to develop effective treatments.
Protein Name: G Protein-coupled Receptor 108
Functions: May play a role in intracellular immune modulation by activating NF-kappaB response and attenuating Toll-like-receptor response
The "GPR108 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GPR108 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
GPR119 | GPR12 | GPR132 | GPR135 | GPR137 | GPR137B | GPR137C | GPR139 | GPR141 | GPR142 | GPR143 | GPR146 | GPR148 | GPR149 | GPR15 | GPR150 | GPR151 | GPR152 | GPR153 | GPR155 | GPR156 | GPR157 | GPR158 | GPR158-AS1 | GPR15LG | GPR160 | GPR161 | GPR162 | GPR17 | GPR171 | GPR173 | GPR174 | GPR176 | GPR179 | GPR18 | GPR180 | GPR182 | GPR183 | GPR19 | GPR199P | GPR20 | GPR21 | GPR22 | GPR25 | GPR26 | GPR27 | GPR3 | GPR31 | GPR32 | GPR33 | GPR34 | GPR35 | GPR37 | GPR37L1 | GPR39 | GPR4 | GPR42 | GPR45 | GPR50 | GPR52 | GPR55 | GPR6 | GPR61 | GPR62 | GPR63 | GPR65 | GPR68 | GPR75 | GPR75-ASB3 | GPR78 | GPR79 | GPR82 | GPR83 | GPR84 | GPR84-AS1 | GPR85 | GPR87 | GPR88 | GPR89A | GPR89B | GPRACR | GPRASP1 | GPRASP2 | GPRASP3 | GPRC5A | GPRC5B | GPRC5C | GPRC5D | GPRC5D-AS1 | GPRC6A | GPRIN1 | GPRIN2 | GPRIN3 | GPS, PLAT and transmembrane domain-containing protein | GPS1 | GPS2 | GPS2P1 | GPSM1 | GPSM2 | GPSM3
